VAY-736 Market Summary
"Key Factors Driving VAY-736 Growth
1. First-in-class opportunity in Sjögren’s disease (major unmet need)
• Phase III NEPTUNUS-1 and NEPTUNUS-2 trials met primary endpoints, showing statistically significant reduction in disease activity.
• The drug has potential to become the first targeted therapy approved for Sjögren’s disease, a condition with no approved disease-modifying treatments.
• Sjögren’s is a chronic, systemic autoimmune disease with high unmet need, supporting strong pricing and rapid uptake post-approval.
2. Strong and consistent Phase III efficacy across multiple indications
• In immune thrombocytopenia (ITP), VAY736:
o Extended disease control by 45%
o Achieved 62% sustained platelet response vs 39% placebo
• Demonstrated durable responses with limited dosing (4 monthly doses), suggesting differentiation vs chronic therapies.
3. Novel dual mechanism of action (differentiation vs competitors)
• Combines:
o B-cell depletion (ADCC)
o BAFF-R inhibition (blocks B-cell survival signals)
4. Broad pipeline across multiple autoimmune diseases
VAY736 is being developed in:
• Sjögren’s disease (lead indication)
• Immune thrombocytopenia (ITP)
• Systemic lupus erythematosus (SLE)
• Lupus nephritis
• Autoimmune hemolytic anemia
5. Favorable regulatory momentum
• Fast Track designation (FDA) and planned global submissions post-Phase III
• Regulatory submissions for ITP expected around 2027
VAY-736 Recent Developments
• In October 2025, Novartis presented new Ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease, at a late-breaker presentation during the American College of Rheumatology Convergence congress. Ianalumab 300 mg monthly delivered a clinically meaningful benefit in the global NEPTUNUS-1 and NEPTUNUS-2 Phase III trials, showing both improvement in disease activity and reductions in patient burden.
• In August 2025, Novartis announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids. Ianalumab plus eltrombopag, compared to placebo plus eltrombopag, significantly prolonged the time to treatment failure (TTF), the primary endpoint that assesses how long patients maintain safe platelet levels during and after the treatment period.
“VAY-736 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of VAY-736 for potential indication like Autoimmune haemolytic anaemia, Idiopathic thrombocytopenic purpura, Lupus nephritis, Sjogren’s syndrome, Systemic lupus erythematosus, Autoimmune hepatitis, Hidradenitis suppurativa, and Rheumatoid arthritis in the 7MM. A detailed picture of VAY-736’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the VAY-736 for potential indications. The VAY-736 market report provides insights about VAY-736’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current VAY-736 performance, future market assessments inclusive of the VAY-736 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of VAY-736 sales forecasts, along with factors driving its market.
VAY-736 Drug Summary
VAY-736 (also known as Ianalumab) is a fully human monoclonal antibody targeting the B-cell activating factor receptor (BAFF-R), developed by Novartis for the treatment of autoimmune diseases, particularly Sjögren’s syndrome and systemic lupus erythematosus. By binding to BAFF-R on B cells, VAY736 exerts a dual mechanism of action: it blocks BAFF-mediated survival and proliferation signals while simultaneously inducing direct B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC). This targeted approach reduces pathogenic B-cell activity, which plays a central role in autoantibody production and chronic inflammation in these conditions. VAY736 is administered via subcutaneous injection and is currently under clinical development, with multiple Phase II and Phase III trials evaluating its efficacy and safety, particularly in patients with moderate-to-severe disease who have limited treatment options. Its differentiated mechanism and potential for sustained B-cell modulation position it as a promising next-generation biologic therapy in the autoimmune treatment landscape. The report provides VAY-736’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the VAY-736 Market Report
The report provides insights into:
• A comprehensive product overview including the VAY-736 MoA, description, dosage and administration, research and development activities in potential indication like Autoimmune haemolytic anaemia, Idiopathic thrombocytopenic purpura, Lupus nephritis, Sjogren’s syndrome, Systemic lupus erythematosus, Autoimmune hepatitis, Hidradenitis suppurativa, and Rheumatoid arthritis.
• Elaborated details on VAY-736 regulatory milestones and other development activities have been provided in VAY-736 market report.
• The report also highlights VAY-736‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The VAY-736 market report also covers the patents information, generic entry and impact on cost cut.
• The VAY-736 market report contains current and forecasted VAY-736 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The VAY-736 market report also features the SWOT analysis with analyst views for VAY-736 in potential indications.
Methodology
The VAY-736 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
VAY-736 Analytical Perspective by DelveInsight
• In-depth VAY-736 Market Assessment
This VAY-736 sales market forecast report provides a detailed market assessment of VAY-736 for potential indication like Autoimmune haemolytic anaemia, Idiopathic thrombocytopenic purpura, Lupus nephritis, Sjogren’s syndrome, Systemic lupus erythematosus, Autoimmune hepatitis, Hidradenitis suppurativa, and Rheumatoid arthritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted VAY-736 sales data uptil 2034.
• VAY-736 Clinical Assessment
The VAY-736 market report provides the clinical trials information of VAY-736 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
VAY-736 Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
VAY-736 Market Potential & Revenue Forecast
• Projected market size for the VAY-736 and its key indications
• Estimated VAY-736 sales potential (VAY-736 peak sales forecasts)
• VAY-736 Pricing strategies and reimbursement landscape
VAY-736 Competitive Intelligence
• Number of competing drugs in development (pipeline analysis)
• VAY-736 Market positioning compared to existing treatments
• VAY-736 Strengths & weaknesses relative to competitors
VAY-736 Regulatory & Commercial Milestones
• VAY-736 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity
VAY-736 Clinical Differentiation
• VAY-736 Efficacy & safety advantages over existing drugs
• VAY-736 Unique selling points
VAY-736 Market Report Highlights
• In the coming years, the VAY-736 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The VAY-736 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VAY-736’s dominance.
• Other emerging products for Autoimmune haemolytic anaemia, Idiopathic thrombocytopenic purpura, Lupus nephritis, Sjogren’s syndrome, Systemic lupus erythematosus, Autoimmune hepatitis, Hidradenitis suppurativa, and Rheumatoid arthritis are expected to give tough market competition to VAY-736 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VAY-736 in potential indications.
• Analyse VAY-736 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted VAY-736 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of VAY-736 in potential indications.
Key Questions
• What is the class of therapy, route of administration and mechanism of action of VAY-736? How strong is VAY-736’s clinical and commercial performance?
• What is VAY-736’s clinical trial status in each individual indications such as Autoimmune haemolytic anaemia, Idiopathic thrombocytopenic purpura, Lupus nephritis, Sjogren’s syndrome, Systemic lupus erythematosus, Autoimmune hepatitis, Hidradenitis suppurativa, and Rheumatoid arthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VAY-736 Manufacturers?
• What are the key designations that have been granted to VAY-736 for potential indications? How are they going to impact VAY-736’s penetration in various geographies?
• What is the current and forecasted VAY-736 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of VAY-736 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to VAY-736 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is VAY-736? What is the duration of therapy and what are the geographical variations in cost per patient?
